Ilya Rachman
| Ilya Rachman | |
|---|---|
 File:Ilya Rachman.jpeg | |
| Born | |
| 🏡 Residence | Los Angeles, California, United States |
| 🏳️ Nationality | American |
| 🏫 Education | University of Iowa; University of Illinois Chicago; University of California, Los Angeles |
| 💼 Occupation | Physician-scientist, cell biologist, biotechnology executive |
| 📆 Years active | 2012–present |
| 👔 Employer | Immix Biopharma, Inc. |
| Known for | Founder, Chairman, CEO and Chief Scientific Officer of Immix Biopharma |
Ilya M. Rachman is an American physician-scientist, cell biologist and biotechnology executive. He founded Immix Biopharma, Inc. in 2012 and has served as the company's chairman and chief executive officer since its establishment. In March 2026, he additionally assumed the position of chief scientific officer, taking on responsibilities related to the company's scientific research and therapeutic development activities.
Early life and background
Rachman pursued his early education in the United States and completed his undergraduate studies at the University of Iowa. He is an American citizen and is based in Los Angeles, California.
His interest in medical research and therapeutic innovation developed through his professional experience in clinical medicine. While treating patients with serious health conditions, he encountered cases in which available treatment options were limited. These experiences contributed to his interest in developing new medical therapies and eventually led him towards biotechnology entrepreneurship.
Education and academic training
Rachman earned a Bachelor of Science degree from the University of Iowa. He continued his education at the University of Illinois Chicago, where he completed a combined Doctor of Medicine and Doctor of Philosophy (MD/PhD) programme. His doctoral research focused on neuroendocrinology.
He later completed an Executive MBA at the University of California, Los Angeles (UCLA). His academic and professional training also included experience at UCLA Health.
His educational background combines medical training, scientific research and business administration, providing experience across clinical practice, biomedical research and corporate management.
Medical and research career
Rachman began his professional career in medicine before moving into biotechnology and pharmaceutical research. He worked in physician-scientist positions at Cedars-Sinai Medical Center and UCLA Health, combining clinical experience with scientific investigation.
His areas of professional experience include clinical medicine, neuroendocrinology and experimental oncology. He also founded a clinical research organisation that participated in pharmaceutical research programmes, including Phase III and Phase IV clinical trials.
Alongside his medical work, Rachman has pursued research in cell biology and related scientific disciplines. His academic publications are listed on his Google Scholar profile, and he is named as an inventor on multiple patents associated with Immix Biopharma.
Immix Biopharma
Company establishment
In 2012, Rachman founded Immix Biopharma, Inc., a biotechnology company established to pursue the development of medical treatments. The company's initial research activities were primarily associated with oncology and the investigation of potential therapeutic candidates.
Over time, its research strategy expanded to include advanced cellular therapies and immune-based approaches for serious and rare diseases.
Rachman has remained the company's chairman and chief executive officer since its founding. In March 2026, he also assumed the position of chief scientific officer, expanding his involvement in the organisation's scientific and research activities.
Corporate and scientific leadership
As the founder and senior executive of Immix Biopharma, Rachman oversees the company's corporate direction and contributes to its scientific development strategy.
His responsibilities include guiding research priorities, supporting the advancement of therapeutic candidates and overseeing the company's broader business objectives. His leadership combines his background in clinical medicine and biomedical research with experience in biotechnology management.
Research and development in AL amyloidosis
Immix Biopharma has focused part of its clinical development activities on AL amyloidosis, a rare disorder involving abnormal plasma cells that produce immunoglobulin light chains. These proteins may accumulate in organs such as the heart, kidneys and liver, potentially resulting in progressive tissue damage.
The company's research strategy involves investigating therapeutic approaches that target the abnormal cells responsible for producing these proteins. Its development activities include cellular immunotherapy and other immune-based treatment technologies.
NXC-201
NXC-201 is Immix Biopharma's principal clinical development candidate. It is an investigational B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy being studied for relapsed or refractory AL amyloidosis.
The treatment incorporates a proprietary CD3ζ signalling domain, a CD8 hinge and a binder-based design intended to function as a "digital filter" to limit non-specific immune activation.
Its therapeutic approach is designed to enable engineered T cells to recognise and eliminate abnormal plasma cells responsible for producing disease-associated light chains.
As chief scientific officer, Rachman is involved in the scientific direction of Immix Biopharma's research and development programmes, including the company's work on NXC-201.
Executive responsibilities and professional experience
Rachman's professional activities encompass medical research, biotechnology development and corporate leadership. His work at Immix Biopharma involves coordinating scientific objectives with the company's wider operational and strategic priorities.
His professional background includes experience in:
- Clinical medicine and patient care;
- Physician-scientist research;
- Neuroendocrinology;
- Cell biology;
- Experimental oncology;
- Pharmaceutical research and clinical trials;
- Biotechnology company management;
- Scientific and corporate strategy; and
- Executive leadership of a publicly listed biotechnology company.
His combined medical, research and management experience informs his involvement in the development of new therapeutic approaches and the company's long-term business direction.
Scientific publications and patents
Rachman's research background includes academic work in neuroendocrinology, experimental oncology and cell biology. His scholarly publications and research activities are available through his Google Scholar profile.
He is also identified as an inventor on patents associated with Immix Biopharma. These intellectual-property activities relate to the company's research and development work in biotechnology and cellular therapies.
